MYUNGMOON Pharm co.,Ltd reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 1,971.6 million compared to KRW 2,209.14 million a year ago. Net loss was KRW 938.9 million compared to net income of KRW 93.93 million a year ago. Basic loss per share from continuing operations was KRW 28 compared to basic earnings per share from continuing operations of KRW 3 a year ago. Basic loss per share was KRW 28 compared to basic earnings per share of KRW 3 a year ago.
For the nine months, sales was KRW 6,197.42 million compared to KRW 6,372.39 million a year ago. Net loss was KRW 493.16 million compared to net income of KRW 3,235.24 million a year ago. Basic loss per share from continuing operations was KRW 15 compared to basic earnings per share from continuing operations of KRW 96 a year ago. Basic loss per share was KRW 15 compared to basic earnings per share of KRW 96 a year ago.